ArticleHematological oncology2022

Oral eltrombopag versus subcutaneous recombinant human thrombopoietin for promoting platelet engraftment after allogeneic stem cell transplantation: A prospective, non-inferiority, randomized controlled trial.

Bingbing Wen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.